At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 138 target
Drug / intervention
BL-M07D1drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M07D1 for Injection in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies
In Brief
A Phase 2 clinical trial evaluating BL-M07D1 for Gynecological Malignancies. Currently recruiting, targeting 138 participants across 1 site.
Detailed Summary
This study is a single-arm, open, multicenter, non-randomized phase Ib/II clinical study evaluating the efficacy and safety of BL-M07D1 for injection in patients with HER2-expressing recurrent or metastatic gynecologic malignancies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGynecological Malignancies
CountriesChina
CollaboratorsBaili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Timeline
Phase 2Recruiting
20242025202620272028
First PostedNov 2023
Enrollment StartFeb 2024
TodayJul 2026
Primary CompletionDec 2026
Study CompletionDec 2027
First PostedNov 14, 2023
Enrollment StartFeb 29, 2024
Primary CompletionDec 1, 2026
Study CompletionDec 1, 2027
TodayJul 1, 2026
Enrollment to primary: 2.8 yearsPosted 2.6 years agoPrimary completion in 5 months
Interventions
BL-M07D1drug
Administration by intravenous infusion